1 Department of Cell Biology, National Translational Science Center for Molecular Medicine, State Key Laboratory of Cancer Biology, Fourth Military Medical University , Xi'an, China .
2 State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China .
Hum Gene Ther. 2018 Feb;29(2):151-159. doi: 10.1089/hum.2017.212.
As part of oncolytic virotherapy to treat cancer, oncolytic viruses (OVs) can selectively infect tumor cells to promote oncolysis of cancer cells, local immunological reactions, and systemic antitumor immunity with minimal toxicity to normal tissues. The immunostimulatory properties of OVs provide enormous benefits for the treatment of cancer. A variety of OVs, including genetically engineered and natural viruses, have shown promise in preclinical models and clinical studies. In 2005, the China Food and Drug Administration approved its first OV drug, Oncorine (H101), for treatment of advanced head and neck cancer. To explore new treatment strategies, >200 recombinant or natural OVs are undergoing in-depth investigation in China, and >250 oncolytic virotherapy-related reports from the OV community in China have been published in the past 5 years. These studies investigated a variety of exogenous genes and combination therapeutic strategies to enhance the treatment effects of OVs. To date, five clinical trials covering four OV agents (Oncorine, OrienX010, KH901, and H103) are ongoing, and additional OV agents are awaiting approval for clinical trials in China. Overall, this research emphasizes that combination therapy, especially tumor immunotherapy coupled with effective system administration strategies, can promote the development of oncolytic virotherapies. This article focuses on studies that were carried out in China in order to give an overview of the past, present, and future of oncolytic virotherapy in China.
作为溶瘤病毒治疗癌症的一部分，溶瘤病毒（OVs）可以选择性地感染肿瘤细胞，促进癌细胞的溶瘤作用、局部免疫反应和全身抗肿瘤免疫，同时对正常组织的毒性最小。OVs 的免疫刺激特性为癌症治疗提供了巨大的益处。多种 OVs，包括基因工程和天然病毒，在临床前模型和临床研究中显示出了希望。2005 年，中国食品药品监督管理局批准了其首个 OV 药物，恩度（H101），用于治疗晚期头颈部癌症。为了探索新的治疗策略，中国正在深入研究超过 200 种重组或天然 OVs，过去 5 年，中国 OV 社区发表了超过 250 篇溶瘤病毒治疗相关报告。这些研究调查了各种外源性基因和联合治疗策略，以增强 OVs 的治疗效果。迄今为止，涵盖四种 OV 制剂（恩度、奥欣妥 010、KH901 和 H103）的五项临床试验正在进行中，另外还有几种 OV 制剂正在等待在中国获得临床试验批准。总的来说，这项研究强调了联合治疗，特别是肿瘤免疫治疗与有效的系统给药策略相结合，可以促进溶瘤病毒治疗的发展。本文重点介绍了在中国开展的研究，以便全面概述中国溶瘤病毒治疗的过去、现在和未来。
